191 related articles for article (PubMed ID: 32207672)
1. Treatment of Smoldering Multiple Myeloma: Expectant Observation Should Still Be the Standard.
Fonseca R; Gonzalez-Velez M
Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-7. PubMed ID: 32207672
[TBL] [Abstract][Full Text] [Related]
2. Smoldering Multiple Myeloma: To Treat or Not to Treat.
Kapoor P; Rajkumar SV
Cancer J; 2019; 25(1):65-71. PubMed ID: 30694862
[TBL] [Abstract][Full Text] [Related]
3. State of the science in smoldering myeloma: Should we be treating in the clinic?
Hill E; Dew A; Kazandjian D
Semin Oncol; 2019 Apr; 46(2):112-120. PubMed ID: 31072611
[TBL] [Abstract][Full Text] [Related]
4. Smoldering multiple myeloma: evolving diagnostic criteria and treatment strategies.
Visram A; Cook J; Warsame R
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):673-681. PubMed ID: 34889380
[TBL] [Abstract][Full Text] [Related]
5. Understanding high-risk smoldering multiple myeloma.
Kreiniz N; Gertz MA
Leuk Lymphoma; 2023; 64(8):1361-1372. PubMed ID: 37229535
[TBL] [Abstract][Full Text] [Related]
6. Timing treatment for smoldering myeloma: is earlier better?
Hernández JÁ; Martínez-López J; Lahuerta JJ
Expert Rev Hematol; 2019 May; 12(5):345-354. PubMed ID: 30907176
[TBL] [Abstract][Full Text] [Related]
7. The Role of Early Intervention in High-Risk Smoldering Myeloma.
Joseph NS; Dhodapkar MV; Lonial S
Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-9. PubMed ID: 32182141
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma (SMM): a practical guide to management.
Maciocia N; Wechalekar A; Yong K
Hematol Oncol; 2017 Dec; 35(4):432-439. PubMed ID: 27804161
[TBL] [Abstract][Full Text] [Related]
9. How I approach smoldering multiple myeloma.
Vaxman I; Gertz MA
Blood; 2022 Aug; 140(8):828-838. PubMed ID: 35576526
[TBL] [Abstract][Full Text] [Related]
10. The consultant's guide to smoldering multiple myeloma.
Thorsteinsdottir S; Kristinsson SY
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):551-559. PubMed ID: 36485144
[TBL] [Abstract][Full Text] [Related]
11. Progress in the Management of Smoldering Multiple Myeloma.
Schmidt TM; Callander NS
Curr Hematol Malig Rep; 2021 Apr; 16(2):172-182. PubMed ID: 33983517
[TBL] [Abstract][Full Text] [Related]
12. 2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde.
Musto P; Engelhardt M; Caers J; Bolli N; Kaiser M; Van de Donk N; Terpos E; Broijl A; De Larrea CF; Gay F; Goldschmidt H; Hajek R; Vangsted AJ; Zamagni E; Zweegman S; Cavo M; Dimopoulos M; Einsele H; Ludwig H; Barosi G; Boccadoro M; Mateos MV; Sonneveld P; Miguel JS
Haematologica; 2021 Nov; 106(11):2799-2812. PubMed ID: 34261295
[TBL] [Abstract][Full Text] [Related]
13. Diagnosis and management of smoldering multiple myeloma: the razor's edge between clonality and cancer.
Muchtar E; Kumar SK; Magen H; Gertz MA
Leuk Lymphoma; 2018 Feb; 59(2):288-299. PubMed ID: 28592156
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic Advances in the Management of Smoldering Myeloma.
Khan R; Zahid U; Kollu V; Jahan N; Ali M; Tricot G; Anwer F
Am J Ther; 2020; 27(2):e194-e203. PubMed ID: 31842112
[TBL] [Abstract][Full Text] [Related]
15. Smoldering multiple myeloma: biology, clinical manifestations and management.
Nsiala L; Bobin A; Levy A; Gruchet C; Sabirou F; Gardeney H; Cailly L; Manier S; Moya N; Tomowiak C; Guidez S; Leleu X; Decaux O
Leuk Lymphoma; 2022 Mar; 63(3):518-529. PubMed ID: 34672244
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal gammopathies of unknown significance and smoldering myeloma: Assessment and management of the elderly patients.
González-Calle V; Mateos MV
Eur J Intern Med; 2018 Dec; 58():57-63. PubMed ID: 29907380
[TBL] [Abstract][Full Text] [Related]
17. Smoldering Multiple Myeloma: Who and When to Treat.
Mateos MV; González-Calle V
Clin Lymphoma Myeloma Leuk; 2017 Nov; 17(11):716-722. PubMed ID: 28709797
[TBL] [Abstract][Full Text] [Related]
18. Mode of progression in smoldering multiple myeloma: a study of 406 patients.
Abdallah NH; Lakshman A; Kumar SK; Cook J; Binder M; Kapoor P; Dispenzieri A; Gertz MA; Lacy MQ; Hayman SR; Buadi FK; Dingli D; Lin Y; Kourelis T; Warsame R; Bergsagel L; Rajkumar SV
Blood Cancer J; 2024 Jan; 14(1):9. PubMed ID: 38228628
[TBL] [Abstract][Full Text] [Related]
19. Smoldering multiple myeloma: the role of different scoring systems in identifying high-risk patients in real-life practice.
Cocito F; Mangiacavalli S; Ferretti VV; Cartia CS; Ganzetti M; Benveuti P; Pompa A; Catalano M; Fugazza E; Landini B; Arcaini L; Corso A
Leuk Lymphoma; 2019 Dec; 60(12):2968-2974. PubMed ID: 31169049
[TBL] [Abstract][Full Text] [Related]
20. Pseudohyperphosphatemia in a patient with incidentally identified progression of smoldering myeloma.
Francis ER; Chen F; Kidacki M; Miller R; Alkhasoneh M; Talamo G; Straub M; Klinefelter K; Kodali N; Zhu Y
Clin Chim Acta; 2018 Dec; 487():306-308. PubMed ID: 30315756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]